December 16, 2025 · Form 4 insider transaction
Bazemore Robert B bought 123,731 shares of AKARI THERAPEUTICS PLC, a transaction worth N/A. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 2 days after the transaction.
Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.; On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.; The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.; The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.